The Analgesics Market was estimated at USD 40.80 billion in 2023 and is expected to reach at USD 63.57 billion by 2031, and develop at a CAGR of 5.7% over the forecast period 2024-2031.
The analgesics market is poised for significant growth driven by a number of factors like the rising prevalence of chronic conditions like arthritis, osteoarthritis, neuropathic diseases, and cancer creates a substantial demand for pain management solutions. This demand is further amplified by the high number of surgeries performed globally, necessitating effective post-surgical pain relief.
Get more information on Analgesics Market - Request Sample Report
Furthermore, the market is witnessing a shift towards safer and more effective pain management options. Regulatory bodies are actively promoting the development of non-addictive alternatives to opioids. Additionally, pharmaceutical companies are heavily invested in research and development, evidenced by the numerous novel analgesics undergoing clinical trials. This focus on innovation aims to deliver pain relief medications with a lower risk of addiction and overdose. Manufacturers are also capitalizing on this growing demand by strategically introducing their products in lucrative markets. For instance, Dr. Reddy's Laboratories' relaunch of their Over-The-Counter naproxen sodium tablets highlights this trend.
Increased Cases of Chronic Diseases
Conditions like cardiovascular disease, cancer, and arthritis cause chronic pain, leading to a higher demand for analgesics for pain management.
Growing Geriatric Population necessitates a larger market for analgesics to manage pain in elderly patients
Governments worldwide are implementing programs to improve access to pain management solutions includes promoting the use of safer analgesics and raising awareness about pain management options
Stricter Regulations on Opioid Abuse
Opioid abuse has become a significant public health concern, leading to stricter regulations and limitations on opioid prescriptions. This restricts the use of some highly effective pain medications.
Limited Medical Infrastructure in Developing Nations
Research and development spending is increasing
Pharmaceutical companies are increasing their investments in research and development to create safer and more effective analgesics with fewer side effects. This opens doors for novel pain management solutions.
Even non-opioid analgesics can have side effects, which can deter patients from using them or lead to complications during treatment. Finding ways to mitigate these side effects is crucial for market growth.
The Russia Ukraine war disrupts pain management across multiple categories such as directly in the conflict zone, injuries cause a surge in musculoskeletal, surgical, and trauma pain, often compounded by limited access to healthcare. Cancer patients face a double threat like disrupted supply chains hindering access to pain medication and damaged healthcare infrastructure impeding treatment. The immense stress experienced by pregnant women in the region can worsen existing pain and complicate childbirth.
The war's reach extends beyond the battlefield with the increased global anxiety can exacerbate chronic pain conditions like fibromyalgia and neuropathic pain. Disruptions in the global supply chain of medications and equipment might indirectly impact access to pain relief for burns, dental issues, and pediatric pain.
The war's mental health impact is another concern that is mental health struggles like depression, anxiety, and PTSD can contribute to chronic pain or hinder managing existing pain. Limited access to pain medication due to the war could also lead to increased opioid dependence. Although, potential benefits exist like the war's focus on pain management could spur investment in research for better pain relief solutions. Additionally, war-torn regions might see a rise in telemedicine, offering remote consultations and support for pain management.
A weak economy can disturb pain management across various conditions. Economic slowdown limit access to crucial treatments like physiotherapy, surgeries, and pain medication. This can worsen pain and slow recovery for those with musculoskeletal, surgical, trauma, and cancer injuries. Pregnant women facing financial hardship might forgo prenatal care or pain relief during childbirth. Reduced insurance coverage or rising healthcare costs during economic downturns make it harder for everyone to afford pain management, impacting all pain types.
The financial burden goes beyond access like stress and anxiety from financial insecurity can exacerbate existing pain or even trigger new ones. People might delay seeking treatment due to cost concerns, leading to a worsening of pain across the board. Burn pain, dental problems, and pediatric pain can also be indirectly impacted. Economic downturn might force individuals to delay treatment for acute pain issues, potentially causing complications and worse pain later.
Investment in pain management might also suffer as budgets for research and development lessen. However, there could be a positive outcome like economic pressures might push a shift towards preventative healthcare to avoid expensive treatments later. This could lead to a focus on stress management and healthy habits to reduce pain risk. Additionally, telemedicine consultations with pain specialists could become a more attractive option due to affordability and convenience, especially in remote areas.
Opioids
Non-opioids
Compound medication
Non-opioid medications, holding the majority share due to several factors such as people prefer them for their lower risk of side effects and wider availability of generic versions. Additionally, both private organizations and governments are promoting their use for pain management. Encouraging results from clinical trials, like the positive phase II results for VX-548 by Vertex Pharmaceuticals, further solidify their dominance.
Oral
Transdermal
Parenteral
Others
The most popular way to take analgesics is orally, accounting for nearly half the market in 2023. This is because swallowing pills is convenient and non-invasive. Pharmaceutical companies are creating new oral options with fewer side effects and lower overdose risk, further propelling this segment's growth. For example, Tris Pharma's cebranopadol showed promising results in reducing addiction compared to opioids.
Musculoskeletal
Migraine
Neuropathic
Obstetrical
Surgical and Trauma
Cancer
Fibromyalgia
Pain due to Burns
Dental/Facial
Pediatric
Others
The leading segment in the analgesics market is surgery & trauma, accounting for over 22% in 2023. This dominance is driven by the rising number of surgeries, traumatic injuries, and pain management initiatives. Government programs and frequent surgeries, like the 200,000 annually in NSW public hospitals alone, highlight the need for analgesics like opioids and non-opioids during and after these procedures.
Hospital pharmacies
Retail pharmacies
Online pharmacies
The dominant channel for analgesics sales is retail pharmacies, holding over half the market share in 2023. This is due to a rise in over-the-counter (OTC) options, easy availability of generic drugs, and more prescriptions driven by pain and injuries. Additionally, new OTC launches like diclofenac, ibuprofen, and ketorolac are propelling this segment's growth.
The analgesics market is led by North America, which held a dominant 31.76% share in 2023. This leadership attributes from a robust presence of major pharmaceutical companies heavily invested in analgesics research and development. Additionally, factors like the high prevalence of chronic pain conditions, frequent surgeries, and the relatively high cost of analgesics in the region contribute to its significant market size. Government efforts to control opioid use also play a role, as they create demand for novel and safer pain management solutions.
However, the Asia Pacific region is poised for the fastest growth in the coming years. This is driven by a number of factors like the growing number of people with chronic diseases, a rapidly expanding elderly population, and the economic development of the region are all creating a surge in demand for analgesics. Furthermore, unmet medical needs within the patient population and increasing investments by pharmaceutical companies in the region position Asia Pacific for a significant rise in the analgesics market.
Need any customization research on Analgesics Market - Enquiry Now
REGIONAL COVERAGE:
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of the Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
Some of the major key players are as follows: Johnson and johnson, Novartis AG, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Bayer AG, Endo International plc, AbbVie Inc., Assertio Holdings, Inc., GlaxoSmithKline plc, Janssen Global Services, LLC, Reckitt Benckiser Group, Viatris Inc. and other players.
RECENT DEVELOPMENTS:
In March 2023 Pfizer's ZAVZPRET Approval, this FDA-approved nasal spray using a novel approach (CGRP receptor antagonist) for treating acute migraines in adults indicates a positive outlook for the analgesics market. New and effective pain management options like ZAVZPRET are likely to fuel market growth in the coming years.
In August 2021, Dr. Reddy's Laboratories brought back their over-the-counter (OTC) naproxen sodium tablets in the U.S. market. This relaunch capitalized on the strong consumer demand for the product, as evidenced by its past sales success.
Abbott Laboratories-Company Financial Analysis
| Report Attributes | Details |
|---|---|
| Market Size in 2023 | US$ 40.80 Billion |
| Market Size by 2031 | US$ 63.57 Billion |
| CAGR | CAGR of 5.7% From 2024 to 2031 |
| Base Year | 2023 |
| Forecast Period | 2024-2031 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments |
|
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia, Rest of Latin America) |
| Company Profiles | Johnson and johnson, Novartis AG, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Bayer AG, Endo International plc, AbbVie Inc., Assertio Holdings, Inc., GlaxoSmithKline plc, Janssen Global Services, LLC, Reckitt Benckiser Group, Viatris Inc. |
| DRIVERS |
|
| RESTRAINTS |
|
Ans: - The Analgesics Market size is estimated to reach US$ 63.57 bn by 2031.
Analgesics Market is divided into four segments and they are By Drug type (Opioids, Non-opioids, Compound medication), By Route of Administration (Oral, Transdermal, Parenteral, Others), By Application (Musculoskeletal, Migraine, Neuropathic, Obstetrical, Surgical and Trauma, Cancer, Fibromyalgia, Pain due to Burns, Dental/Facial, Pediatric, Others), By Distribution Channel (Hospital pharmacies, Retail pharmacies, Online pharmacies).
North America dominated the analgesics market.
Manufacturer and service provider, research institutes, university and private libraries, suppliers and distributers.
Ans: - The Analgesics market is expected to grow at a CAGR of 5.7% over the forecast period 2024-2031.
TABLE OF CONTENTS
1. Introduction
1.1 Market Definition
1.2 Scope
1.3 Research Assumptions
2. Industry Flowchart
3. Research Methodology
4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
5. Impact Analysis
5.1 Impact of Russia-Ukraine Crisis
5.2 Impact of Economic Slowdown on Major Countries
5.2.1 Introduction
5.2.2 United States
5.2.3 Canada
5.2.4 Germany
5.2.5 France
5.2.6 UK
5.2.7 China
5.2.8 Japan
5.2.9 South Korea
5.2.10 India
6. Value Chain Analysis
7. Porter’s 5 Forces Model
8. Pest Analysis
9. Analgesics Market Segmentation, By Drug type
9.1 Introduction
9.2 Trend Analysis
9.3 Opioids
9.4 Non-opioids
9.5 Compound medication
10. Analgesics Market Segmentation, By Route of Administration
10.1 Introduction
10.2 Trend Analysis
10.3 Oral
10.4 Transdermal
10.5 Parenteral
10.6 Others
11. Analgesics Market Segmentation, By Application
11.1 Introduction
11.2 Trend Analysis
11.3 Musculoskeletal
11.4 Migraine
11.5 Neuropathic
11.6 Obstetrical
11.7 Surgical and Trauma
11.8 Cancer
11.9 Fibromyalgia
11.10 Pain due to Burns
11.11 Dental/Facial
11.12 Pediatric
11.13 Others
12. Analgesics Market Segmentation, By Distribution Channel
12.1 Introduction
12.2 Trend Analysis
12.3 Hospital pharmacies
12.4 Retail pharmacies
12.5 Online pharmacies
13. Regional Analysis
13.1 Introduction
13.2 North America
13.2.1 Trend Analysis
13.2.2 North America Analgesics Market by Country
13.2.3 North America Analgesics Market By Drug type
13.2.4 North America Analgesics Market By Route of Administration
13.2.5 North America Analgesics Market By Application
13.2.6 North America Analgesics Market By Distribution Channel
13.2.7 USA
13.2.7.1 USA Analgesics Market By Drug type
13.2.7.2 USA Analgesics Market By Route of Administration
13.2.7.3 USA Analgesics Market By Application
13.2.7.4 USA Analgesics Market By Distribution Channel
13.2.8 Canada
13.2.8.1 Canada Analgesics Market By Drug type
13.2.8.2 Canada Analgesics Market By Route of Administration
13.2.8.3 Canada Analgesics Market By Application
13.2.8.4 Canada Analgesics Market By Distribution Channel
13.2.9 Mexico
13.2.9.1 Mexico Analgesics Market By Drug type
13.2.9.2 Mexico Analgesics Market By Route of Administration
13.2.9.3 Mexico Analgesics Market By Application
13.2.9.4 Mexico Analgesics Market By Distribution Channel
13.3 Europe
13.3.1 Trend Analysis
13.3.2 Eastern Europe
13.3.2.1 Eastern Europe Analgesics Market by Country
13.3.2.2 Eastern Europe Analgesics Market By Drug type
13.3.2.3 Eastern Europe Analgesics Market By Route of Administration
13.3.2.4 Eastern Europe Analgesics Market By Application
13.3.2.5 Eastern Europe Analgesics Market By Distribution Channel
13.3.2.6 Poland
13.3.2.6.1 Poland Analgesics Market By Drug type
13.3.2.6.2 Poland Analgesics Market By Route of Administration
13.3.2.6.3 Poland Analgesics Market By Application
13.3.2.6.4 Poland Analgesics Market By Distribution Channel
13.3.2.7 Romania
13.3.2.7.1 Romania Analgesics Market By Drug type
13.3.2.7.2 Romania Analgesics Market By Route of Administration
13.3.2.7.3 Romania Analgesics Market By Application
13.3.2.7.4 Romania Analgesics Market By Distribution Channel
13.3.2.8 Hungary
13.3.2.8.1 Hungary Analgesics Market By Drug type
13.3.2.8.2 Hungary Analgesics Market By Route of Administration
13.3.2.8.3 Hungary Analgesics Market By Application
13.3.2.8.4 Hungary Analgesics Market By Distribution Channel
13.3.2.9 Turkey
13.3.2.9.1 Turkey Analgesics Market By Drug type
13.3.2.9.2 Turkey Analgesics Market By Route of Administration
13.3.2.9.3 Turkey Analgesics Market By Application
13.3.2.9.4 Turkey Analgesics Market By Distribution Channel
13.3.2.10 Rest of Eastern Europe
13.3.2.10.1 Rest of Eastern Europe Analgesics Market By Drug type
13.3.2.10.2 Rest of Eastern Europe Analgesics Market By Route of Administration
13.3.2.10.3 Rest of Eastern Europe Analgesics Market By Application
13.3.2.10.4 Rest of Eastern Europe Analgesics Market By Distribution Channel
13.3.3 Western Europe
13.3.3.1 Western Europe Analgesics Market by Country
13.3.3.2 Western Europe Analgesics Market By Drug type
13.3.3.3 Western Europe Analgesics Market By Route of Administration
13.3.3.4 Western Europe Analgesics Market By Application
13.3.3.5 Western Europe Analgesics Market By Distribution Channel
13.3.3.6 Germany
13.3.3.6.1 Germany Analgesics Market By Drug type
13.3.3.6.2 Germany Analgesics Market By Route of Administration
13.3.3.6.3 Germany Analgesics Market By Application
13.3.3.6.4 Germany Analgesics Market By Distribution Channel
13.3.3.7 France
13.3.3.7.1 France Analgesics Market By Drug type
13.3.3.7.2 France Analgesics Market By Route of Administration
13.3.3.7.3 France Analgesics Market By Application
13.3.3.7.4 France Analgesics Market By Distribution Channel
13.3.3.8 UK
13.3.3.8.1 UK Analgesics Market By Drug type
13.3.3.8.2 UK Analgesics Market By Route of Administration
13.3.3.8.3 UK Analgesics Market By Application
13.3.3.8.4 UK Analgesics Market By Distribution Channel
13.3.3.9 Italy
13.3.3.9.1 Italy Analgesics Market By Drug type
13.3.3.9.2 Italy Analgesics Market By Route of Administration
13.3.3.9.3 Italy Analgesics Market By Application
13.3.3.9.4 Italy Analgesics Market By Distribution Channel
13.3.3.10 Spain
13.3.3.10.1 Spain Analgesics Market By Drug type
13.3.3.10.2 Spain Analgesics Market By Route of Administration
13.3.3.10.3 Spain Analgesics Market By Application
13.3.3.10.4 Spain Analgesics Market By Distribution Channel
13.3.3.11 Netherlands
13.3.3.11.1 Netherlands Analgesics Market By Drug type
13.3.3.11.2 Netherlands Analgesics Market By Route of Administration
13.3.3.11.3 Netherlands Analgesics Market By Application
13.3.3.11.4 Netherlands Analgesics Market By Distribution Channel
13.3.3.12 Switzerland
13.3.3.12.1 Switzerland Analgesics Market By Drug type
13.3.3.12.2 Switzerland Analgesics Market By Route of Administration
13.3.3.12.3 Switzerland Analgesics Market By Application
13.3.3.12.4 Switzerland Analgesics Market By Distribution Channel
13.3.3.13 Austria
13.3.3.13.1 Austria Analgesics Market By Drug type
13.3.3.13.2 Austria Analgesics Market By Route of Administration
13.3.3.13.3 Austria Analgesics Market By Application
13.3.3.13.4 Austria Analgesics Market By Distribution Channel
13.3.3.14 Rest of Western Europe
13.3.3.14.1 Rest of Western Europe Analgesics Market By Drug type
13.3.3.14.2 Rest of Western Europe Analgesics Market By Route of Administration
13.3.3.14.3 Rest of Western Europe Analgesics Market By Application
13.3.3.14.4 Rest of Western Europe Analgesics Market By Distribution Channel
13.4 Asia-Pacific
13.4.1 Trend Analysis
13.4.2 Asia-Pacific Analgesics Market by Country
13.4.3 Asia-Pacific Analgesics Market By Drug type
13.4.4 Asia-Pacific Analgesics Market By Route of Administration
13.4.5 Asia-Pacific Analgesics Market By Application
13.4.6 Asia-Pacific Analgesics Market By Distribution Channel
13.4.7 China
13.4.7.1 China Analgesics Market By Drug type
13.4.7.2 China Analgesics Market By Route of Administration
13.4.7.3 China Analgesics Market By Application
13.4.7.4 China Analgesics Market By Distribution Channel
13.4.8 India
13.4.8.1 India Analgesics Market By Drug type
13.4.8.2 India Analgesics Market By Route of Administration
13.4.8.3 India Analgesics Market By Application
13.4.8.4 India Analgesics Market By Distribution Channel
13.4.9 Japan
13.4.9.1 Japan Analgesics Market By Drug type
13.4.9.2 Japan Analgesics Market By Route of Administration
13.4.9.3 Japan Analgesics Market By Application
13.4.9.4 Japan Analgesics Market By Distribution Channel
13.4.10 South Korea
13.4.10.1 South Korea Analgesics Market By Drug type
13.4.10.2 South Korea Analgesics Market By Route of Administration
13.4.10.3 South Korea Analgesics Market By Application
13.4.10.4 South Korea Analgesics Market By Distribution Channel
13.4.11 Vietnam
13.4.11.1 Vietnam Analgesics Market By Drug type
13.4.11.2 Vietnam Analgesics Market By Route of Administration
13.4.11.3 Vietnam Analgesics Market By Application
13.4.11.4 Vietnam Analgesics Market By Distribution Channel
13.4.12 Singapore
13.4.12.1 Singapore Analgesics Market By Drug type
13.4.12.2 Singapore Analgesics Market By Route of Administration
13.4.12.3 Singapore Analgesics Market By Application
13.4.12.4 Singapore Analgesics Market By Distribution Channel
13.4.13 Australia
13.4.13.1 Australia Analgesics Market By Drug type
13.4.13.2 Australia Analgesics Market By Route of Administration
13.4.13.3 Australia Analgesics Market By Application
13.4.13.4 Australia Analgesics Market By Distribution Channel
13.4.14 Rest of Asia-Pacific
13.4.14.1 Rest of Asia-Pacific Analgesics Market By Drug type
13.4.14.2 Rest of Asia-Pacific Analgesics Market By Route of Administration
13.4.14.3 Rest of Asia-Pacific Analgesics Market By Application
13.4.14.4 Rest of Asia-Pacific Analgesics Market By Distribution Channel
13.5 Middle East & Africa
13.5.1 Trend Analysis
13.5.2 Middle East
13.5.2.1 Middle East Analgesics Market by Country
13.5.2.2 Middle East Analgesics Market By Drug type
13.5.2.3 Middle East Analgesics Market By Route of Administration
13.5.2.4 Middle East Analgesics Market By Application
13.5.2.5 Middle East Analgesics Market By Distribution Channel
13.5.2.6 UAE
13.5.2.6.1 UAE Analgesics Market By Drug type
13.5.2.6.2 UAE Analgesics Market By Route of Administration
13.5.2.6.3 UAE Analgesics Market By Application
13.5.2.6.4 UAE Analgesics Market By Distribution Channel
13.5.2.7 Egypt
13.5.2.7.1 Egypt Analgesics Market By Drug type
13.5.2.7.2 Egypt Analgesics Market By Route of Administration
13.5.2.7.3 Egypt Analgesics Market By Application
13.5.2.7.4 Egypt Analgesics Market By Distribution Channel
13.5.2.8 Saudi Arabia
13.5.2.8.1 Saudi Arabia Analgesics Market By Drug type
13.5.2.8.2 Saudi Arabia Analgesics Market By Route of Administration
13.5.2.8.3 Saudi Arabia Analgesics Market By Application
13.5.2.8.4 Saudi Arabia Analgesics Market By Distribution Channel
13.5.2.9 Qatar
13.5.2.9.1 Qatar Analgesics Market By Drug type
13.5.2.9.2 Qatar Analgesics Market By Route of Administration
13.5.2.9.3 Qatar Analgesics Market By Application
13.5.2.9.4 Qatar Analgesics Market By Distribution Channel
13.5.2.10 Rest of Middle East
13.5.2.10.1 Rest of Middle East Analgesics Market By Drug type
13.5.2.10.2 Rest of Middle East Analgesics Market By Route of Administration
13.5.2.10.3 Rest of Middle East Analgesics Market By Application
13.5.2.10.4 Rest of Middle East Analgesics Market By Distribution Channel
13.5.3 Africa
13.5.3.1 Africa Analgesics Market by Country
13.5.3.2 Africa Analgesics Market By Drug type
13.5.3.3 Africa Analgesics Market By Route of Administration
13.5.3.4 Africa Analgesics Market By Application
13.5.3.5 Africa Analgesics Market By Distribution Channel
13.5.3.6 Nigeria
13.5.3.6.1 Nigeria Analgesics Market By Drug type
13.5.3.6.2 Nigeria Analgesics Market By Route of Administration
13.5.3.6.3 Nigeria Analgesics Market By Application
13.5.3.6.4 Nigeria Analgesics Market By Distribution Channel
13.5.3.7 South Africa
13.5.3.7.1 South Africa Analgesics Market By Drug type
13.5.3.7.2 South Africa Analgesics Market By Route of Administration
13.5.3.7.3 South Africa Analgesics Market By Application
13.5.3.7.4 South Africa Analgesics Market By Distribution Channel
13.5.3.8 Rest of Africa
13.5.3.8.1 Rest of Africa Analgesics Market By Drug type
13.5.3.8.2 Rest of Africa Analgesics Market By Route of Administration
13.5.3.8.3 Rest of Africa Analgesics Market By Application
13.5.3.8.4 Rest of Africa Analgesics Market By Distribution Channel
13.6 Latin America
13.6.1 Trend Analysis
13.6.2 Latin America Analgesics Market by country
13.6.3 Latin America Analgesics Market By Drug type
13.6.4 Latin America Analgesics Market By Route of Administration
13.6.5 Latin America Analgesics Market By Application
13.6.6 Latin America Analgesics Market By Distribution Channel
13.6.7 Brazil
13.6.7.1 Brazil Analgesics Market By Drug type
13.6.7.2 Brazil Analgesics Market By Route of Administration
13.6.7.3 Brazil Analgesics Market By Application
13.6.7.4 Brazil Analgesics Market By Distribution Channel
13.6.8 Argentina
13.6.8.1 Argentina Analgesics Market By Drug type
13.6.8.2 Argentina Analgesics Market By Route of Administration
13.6.8.3 Argentina Analgesics Market By Application
13.6.8.4 Argentina Analgesics Market By Distribution Channel
13.6.9 Colombia
13.6.9.1 Colombia Analgesics Market By Drug type
13.6.9.2 Colombia Analgesics Market By Route of Administration
13.6.9.3 Colombia Analgesics Market By Application
13.6.9.4 Colombia Analgesics Market By Distribution Channel
13.6.10 Rest of Latin America
13.6.10.1 Rest of Latin America Analgesics Market By Drug type
13.6.10.2 Rest of Latin America Analgesics Market By Route of Administration
13.6.10.3 Rest of Latin America Analgesics Market By Application
13.6.10.4 Rest of Latin America Analgesics Market By Distribution Channel
14. Company Profiles
14.1 Johnson and johnson
14.1.1 Company Overview
14.1.2 Financial
14.1.3 Products/ Services Offered
14.1.4 SWOT Analysis
14.1.5 The SNS View
14.2 Novartis AG
14.2.1 Company Overview
14.2.2 Financial
14.2.3 Products/ Services Offered
14.2.4 SWOT Analysis
14.2.5 The SNS View
14.3 Eli Lilly and Company
14.3.1 Company Overview
14.3.2 Financial
14.3.3 Products/ Services Offered
14.3.4 SWOT Analysis
14.3.5 The SNS View
14.4 Teva Pharmaceutical Industries Ltd.
14.4.1 Company Overview
14.4.2 Financial
14.4.3 Products/ Services Offered
14.4.4 SWOT Analysis
14.4.5 The SNS View
14.5 Bayer AG
14.5.1 Company Overview
14.5.2 Financial
14.5.3 Products/ Services Offered
14.5.4 SWOT Analysis
14.5.5 The SNS View
14.6 Endo International plc
14.6.1 Company Overview
14.6.2 Financial
14.6.3 Products/ Services Offered
14.6.4 SWOT Analysis
14.6.5 The SNS View
14.7 AbbVie Inc.
14.7.1 Company Overview
14.7.2 Financial
14.7.3 Products/ Services Offered
14.7.4 SWOT Analysis
14.7.5 The SNS View
14.8 Assertio Holdings, Inc.
14.8.1 Company Overview
14.8.2 Financial
14.8.3 Products/ Services Offered
14.8.4 SWOT Analysis
14.8.5 The SNS View
14.9 GlaxoSmithKline plc
14.9.1 Company Overview
14.9.2 Financial
14.9.3 Products/ Services Offered
14.9.4 SWOT Analysis
14.9.5 The SNS View
14.10 Janssen Global Services, LLC
14.10.1 Company Overview
14.10.2 Financial
14.10.3 Products/ Services Offered
14.10.4 SWOT Analysis
14.10.5 The SNS View
14.11 Reckitt Benckiser Group
14.11.1 Company Overview
14.11.2 Financial
14.11.3 Products/ Services Offered
14.11.4 SWOT Analysis
14.11.5 The SNS View
14.12 Viatris Inc.
14.12.1 Company Overview
14.12.2 Financial
14.12.3 Products/ Services Offered
14.12.4 SWOT Analysis
14.12.5 The SNS View
15. Competitive Landscape
15.1 Competitive Benchmarking
15.2 Market Share Analysis
15.3 Recent Developments
15.3.1 Industry News
15.3.2 Company News
15.3.3 Mergers & Acquisitions
16. Use Case and Best Practices
17. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
The Venous Leg Ulcer (VLU) Treatment Market was valued at USD 4.07 Billion by 2023 and is expected to reach nearly USD 6.85 Billion by 2031, at CAGR 6.7% for the projected year 2024-2031.
The Nanomedicine Market Size was valued at USD 170.47 billion in 2022, and is expected to reach USD 431.21 billion by 2030 and grow at a CAGR of 12.3% over the forecast period 2023-2030.
The eHealth Market Size was valued at USD 346.86 billion in 2023, and is expected to reach USD 1330.55 billion by 2031 and grow at a CAGR of 18.3% over the forecast period 2024-2031.
The Legal Marijuana Market size was valued at USD 21.08 billion in 2023 and is supposed to grow at a CAGR of 25.6% from 2024 to 2031. the legal marijuana market is estimated to reach 130.55 billion by 2031.
The Nutrigenomics Market size was estimated at USD 0.51 billion in 2023 and is expected to reach USD 2.10 billion by 2032 with a growing CAGR of 17.05% during the forecast period of 2024-2032.
The Smart Pulse Oximeters Market Size was valued at USD 1.73 billion in 2022, and is expected to reach USD 3.08 billion by 2030 and grow at a CAGR of 7.5% over the forecast period 2023-2030.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
